Protein levels of SFRP4 measured by immunohistochemistry is discordant in prostate cancer; Horvath et al. 13,14 reported increased expression of membranous SFRP4 staining to be associated with good prognosis, while Mortensen et al. 10 reported cytoplasmic expression to be linked to worse prognosis. This evidence concerns the gene SFRP4 and Familial prostate cancer.